anti-tumor therapy after LT and served as the reference group. Results The 1- and 3-year survival rates were 89.7% and 79.3% with chemotherapy versus 69.0% and 62.1% without chemotherapy. The cumulative 1-year survivalwas significantly increased by chemotherapy（log-rank test，P＝0.043）. Median survival was increased 4.57 months with combination chemotherapy. The 6-month tumor-free survival rate was 24.1% higher with chemotherapy than those without. Cox multivariate analysis showed a significant association between survival and adjuvant chemotherapy（P＝0.033）. The chemotherapy regimen was generally well tolerated. Conclusions Post-LT adjuvant chemotherapy with oxaliplatin/5-FU/CF could not prevent tumor recurrence post-LT but may contribute to the survival improvement of HCC patients who do not meet the Milan criteria. These results should be verified in a largersample with a longer follow-up period.

Objective To construct the mouse chimeric pre-T cells with major histocompatibilitycomplex-Ⅰ（MHC-Ⅰ）gene，and explore the potential of chimeric pre-T cells to alleviate spleen T lymphocyteresponse to allogeneic mouse T cells. Methods BALB/c mouse pre-T cells were cultured. Eukaryotic expressionvectors of C57BL/6 mouse MHC-Ⅰ（pIRES-H-2Db and pIRES-H-2Kb）wereconstructed to transfect BALB/c pre-Tcells. Then the molecular chimeric cells were transfused back to BALB/c mouse. After 7 days，the effect of molecularchimeric cells on spleen T lymphocyte response to allogeneic T cells was observed through mixed lymphocyte culture

（MLC）. Stimulation index（SI）was calculated. Results BALB/c mouse pre-T cells were successfully separatedand cultured. Flow cytometry analysis indicated that H-2Db and H-2Kb protein expression were（14.90±0.56）%and（14.20±0.63）% in pre-T cells group. The result of MLC demonstrated that the SI of T lymphocyte weresignificantly decreased in molecular chimeric cells group（0.764±0.074）compared with empty vector group（0.983±0.081）and non-transfection group（0.994±0.142，both P＜0.05）. There were significances in SI betweenmolecular chimeric cells group and pIRES-H-2Db group（0.859±0.085），pIRES-H-2Kb group（0.860±0.097，both P＜0.05）. Conclusion The molecular chimeric pre-T cells infusion could alleviate spleen T lymphocyte responseto allogeneic T cells.

Objective To evaluate the influence of the cytochrome P450（CYP）3A5 genes of both donorsand recipients on the concentration/dosage ratio（C/D）of tacrolimus in adult liver transplant patients. Methods 51adult liver transplant patients received tacrolimus were included in this study. The CYP3A5 polymorphism（includingdonors and recipients）were measured at the time of transplantation，and then tacrolimus-based immunosuppressivetherapy was started on the basis of each patient's genetic constitution. CYP3A5*1/*1 genotype and *1/*3 genotypewere combined into expressor genotype and *3/*3 genotype was nonexpressor group. The C/D of tacrolimus during3 months after surgery was analyzed in relation to the CYP3A5 genotype. A stepwise regression was used toanalyze the relationship between C/D of tacrolimus and genotype，time course，age，liver weight in liver transplantpatients. Results C/D of tacrolimus in patients with CYP3A5*1 expressed donor was lower than C/D of patients

with CYP3A5*1 unexpressed donor（P＜0.05 or P＜0.01）；C/D in CYP3A5*1-carried patients was also lower than CYP3A5*1 unexpressed patients（all P＜0.01）. C/D in CYP3A5*3/*3 patients with CYP3A5*3/*3 donorwas obviously higher campared with the other 3 groups during 3 months after transplantation（all P＜0.01），andthe difference of C/D in other 3 groups was not statistically significant（all P＞0.05）. The regression equation ：Y（tacrolimus concentration/dose ratio per unit weight）

＝ 1.025 + 0.625 donor genotype + 0.520 receptor genotype +0.021 postoperative length － 0.008 patients with age. Conclusions Those findings suggest that the CYP3A5*1genotype in donors as well as in patients both contributes to inter-individual variation in the C/D of tacrolimus in adultliver transplantation. The factors impacting patient's tacrolimus blood concentrations are donor's CYP3A5 genotype，recipient's CYP3A5 genotype，time course and age . Patients can benefit from setting and adjusting FK506 dosageaccording to CYP3A5 genotype of both donors and recipients.

Objective To investigate the early diagnosis，prophylaxis and treatment principles ofinterstitial pneumonia in renal transplant recipients. Methods 83 kidney transplant recipients who diagnosed withinterstitial pneumonia during the period from 2008 to 2011 in the Urinary Diseases Diagnosis & Treatment Center，First Hospital of Jilin University were enrolled in this study. The difference of prophylaxis，treatment with interstitialpneumonia and the occurrence of interstitial pneumonia after renal transplantation between January - December，2008 and January 2009 - December 2011 were compared. Results There were a total of 138 patients underwentallograft renal transplantation during the period from January 2008 to December 2008，and 38 of the kidney recipientsdeveloped interstitial pneumonia and the incidence rate was 27.54%. There were a total of 435 patients underwent

Objective To evaluate the therapeutic results of percutaneous transhepatic stent angioplasty for portal vein stenosis following liver transplant. Methods From 2005 to 2012，37 patients developed portal vein stenosis following liver transplant. Percutaneous transhepatic angioplasty of the portal vein was performed in allpatients. The clinical data，imaging follow-up data，complications of interventional treatment and prognosis weresummarized. Results In all patients，the percutaneous transhepatic angioplasty were successful. It was placed with7 pieces of self-expanding metallic stents，29 pieces of balloon-expandable coronary stent，

and 1 piece of membranous stent. 1 case of pediatric liver transplant patients was only used balloon angioplasty. 1 case with abdominal hemorrhageof early postoperative（2.70%），diagnosis of hepatic artery hemorrhage by hepatic artery angiography and cured byinterventional embolization. The follow up period ranged from 3 months to 80 months. Portal venous patency was

maintained in 33 patients（1 patient died due to multi organ failure because of concomitant hepatic artery occlusion and ischemic bile duct injury after 3 months，1 patient accept the second liver transplantation because of the biliary tract complications，1 case was placed membranous tent again because of portal vein stent carcinoma bolt，and 1 case with stent restenosis）. Conclusion Percutaneous transhepatic stent angioplasty is an effective and safe method for treatment of portal vein stenosis following liver transplant.

Objects To analyze the expression of somatostatin receptor（SSTR）-2/5 in HBV-relatedhepatocellular carcinomas（HCC）and compare its clinicopathological features and follow-up data. Methods 22patients diagnosed with HCC between February 2008 and July 2010 underwent radical liver resection. Expression ofSSTR-2/5 in HCC and adjacent cirrhotic tissues were examined by immunohistochemistry and real time polymerasechain reaction（PCR）. Moreover，the relationship between SSTR expression and clinicopathological features werealso compared. The patients had routine follow-up exams until cancer reoccurred. Results Adjacent cirrhoticliver and HCC expressed SSTR-2/5. Compared to adjacent cirrhotic liver tissues，expression of SSTR-2/5 in tumorswere significantly lower〔SSTR-2 mRNA（RQ）：1.89±0.74 vs. 2.54±0.80，SSTR-5 mRNA（RQ）：3.61±1.66vs. 6.78±4.27 ；SSTR-2 protein ：68.2%（12/22）vs. 95.5%（21/22），SSTR-2/5 protein ：both 95.5%（21/22），all P＜0.05〕. The mean progression free survival for all patients was 27.3 months. The high SSTR-2/5 expressiongroup had significantly improved the progression free survival compared to the low expression group（log-rank＝4.08，P＝0.043）. Conclusions Down regulation of SSTR transcription may result in loss of a tumor suppressive.Characterization of SSTR expression can be used as a useful parameter to evaluate the prognosis of HCC.

Objective To investigate the effects of oxygen delivery（DO2）-directed hemodynamicmanagement on oxygen metabolism during orthotropic liver transplantation（OLT）without veno-venous bypass in thepatients with different degrees of hepatic insufficiency. Methods 50 patients scheduled non veno-venous bypassOLT were divided into 3 groups according to the Pugh-Child scores ，class A（group A，12 patients），class B（groupB，18 patients），class C（group C，20 patients）. Left radial artery was cannulated before induction of anesthesia，then Swan-Ganz catheter was inserted in the pulmonary artery via right internal jugular vein. Cardiac index（CI）wasmaintained more than 50 ml/（s·m2）and mean arterial pressure more than 60 mm Hg（1 mm Hg＝0.133 kPa）in allpatients. Arterial partial pressure of oxygen（PaO2），mixed venous saturation（SvO2），CI，DO2，oxygen consumption（VO2）and oxygen extract rate（ERO2）were measured or calculated after anesthesia and before surgical incision（T1，baseline），at 10 minutes before anhepatic phase（T2），30 minutes after onset of anhepatic phase（T3），30 minutesafter neohepatic phase（T4）and the end of surgical procedure（T5）. Results In the three groups，VO2，SvO2，and DO2 during T3 showed substantial decrease in comparison with T1（P＜0.05 or P＜0.01），then VO2 markedly increasedduring T4 in comparison with T3（all P ＜ 0.05），which recovered to T1 up to the end of T5. ERO2 increased significantlyduring the T3 in comparison with T1 in group B and C（both P ＜ 0.05）. Moreover，there were significant differences amongthree groups during T3，which mainly manifested the SvO2 and DO2 were much lower in group B and C than in group A，while ERO2 was much higher in group B and C than group A（all P ＜ 0.05）. The length of hospital stay was increasedsequentially from group A to group C. Conclusions The tendency of the whole changes in oxygen metabolism of thepatients with different degrees hepatic insufficiency during OLT is consistent during DO2-directed management patterns ofhemodynamics，and abnormality of oxygen metabolism occurs more severely in anhepatic phase. The changes of DO2 andERO2 in patients with Pugh-Child scores Class B and C were more serious than Class A.